Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin Price-Fixing $335 Mil. Settlement Reached For Indirect Purchasers

This article was originally published in The Tan Sheet

Executive Summary

Twenty-four states and U.S. jurisdictions will use $145.6 mil. in proceeds from vitamin price-fixing settlements to fund health, education and scientific programs such as prenatal care and nutrition research.
Advertisement

Related Content

Vitamin C Price-Fixing Case Could Apply U.S. Antitrust Laws To Chinese Firms
Supreme Court Takes Up Vitamin Antitrust Case Appeal
DSM To Acquire Leading Position In Vitamin Supply Market With Roche Deal
Vitamin Price-Fixing Funds Support Research On Supplements, Cancer
Mass. vitamin settlement
Vitamin litigation
Roche Vitamins New Production Methods Targeted To Reduce Costs
BASF Global Vitamin Presence Strengthened With Takeda Combination
BASF Global Vitamin Presence Strengthened With Takeda Combination
Vitamin Price-Fixing $242 Mil. Class Settlement Fund Approved

Topics

Advertisement
UsernamePublicRestriction

Register

PS091781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel